LogicBio Therapeutics, Inc (LOGC)

Etorro trading 970x250
LogicBio Therapeutics, Inc (LOGC) Logo

About LogicBio Therapeutics, Inc

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient’s genome to provide a therapeutic effect. The company’s lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. It has a collaboration with Children’s Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Address: 65 Hayden Avenue, Lexington, MA, United States, 02421

LogicBio Therapeutics, Inc News and around…

Latest news about LogicBio Therapeutics, Inc (LOGC) common stock and company :

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
20 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We're closing in on the end of the week for trading as we go over the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

12 Health Care Stocks Moving In Thursday's Pre-Market Session
19 May, 2022 FinancialContent

Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 28.8% to $3.22 during Thursday's pre-market ...

LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference
17 May, 2022 Yahoo! Finance

LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. The pre-recorded presentation will be available for on-demand viewing beginning at 7:00 a.m. ET on Tuesday, May 24, 2022.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
17 May, 2022 FinancialContent

Gainers Allogene Therapeutics (NASDAQ:ALLO) shares increased by 12.7% to $7.98 during Tuesday's pre-market session. ...

LogicBio Therapeutics: Q1 Earnings Insights
16 May, 2022 FinancialContent

LogicBio Therapeutics (NASDAQ:LOGC) reported its Q1 earnings results on Monday, May 16, 2022 at 08:30 AM. Here's what investors need to ...

LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates
16 May, 2022 Yahoo! Finance

LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage company advancing a diversified pipeline of genetic medicines addressing rare disorders from infancy through adulthood, today reported financial results for the quarter ended March 31, 2022, and highlighted recent business updates.

LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting
11 May, 2022 Yahoo! Finance

LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that it will present four abstracts highlighting the company's GeneRide technology in preclinical hereditary tyrosinemia type 1 (HT1) models and optimized adeno-associated virus (AAV) manufacturing processes during the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting, held May 16-19, 2022, in Washington D.C. and virtually.

103 Biggest Movers From Yesterday
11 May, 2022 FinancialContent

Gainers Biohaven Pharmaceutical Holding Company Ltd. (NASDAQ: BHVN) shares surged 68.4% to close at $140.00 on Tuesday. Pfizer ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
10 May, 2022 FinancialContent

Gainers Biohaven Pharma Hldgs (NYSE:BHVN) stock moved upwards by 70.0% to $141.34 during Tuesday's regular session. ...

77 Stocks Moving In Tuesday's Mid-Day Session
10 May, 2022 FinancialContent

Gainers Biohaven Pharmaceutical Holding Company Ltd. (NASDAQ: BHVN) shares jumped 70.8% to $142.01. Pfizer Inc (NYSE: PFE) will ...

30 Stocks Moving in Tuesday's Pre-Market Session
10 May, 2022 FinancialContent

Gainers Vroom, Inc. (NASDAQ: VRM) shares rose 38% to $1.49 in pre-market trading after the company reported better-than-expected ...

90 Biggest Movers From Yesterday
10 May, 2022 FinancialContent

Gainers Hemisphere Media Group, Inc(NASDAQ: HMTV) shares climbed 78.8% to close at $6.74 on Monday after the company ...

12 Health Care Stocks Moving In Monday's Intraday Session
09 May, 2022 FinancialContent

Gainers Blue Water Vaccines (NASDAQ:BWV) shares increased by 43.6% to $5.4 during Monday's regular session. Trading ...

Why LogicBio Therapeutics Shares Are Popping Off Today
09 May, 2022 FinancialContent

LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher by 63.48% at $0.81 after the company announced the FDA lifted the ...

LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatric Trial
09 May, 2022 FinancialContent

TheFDA has lifted the clinical holdonLogicBio Therapeutics Inc's(NASDAQ: LOGC) LB-001 Investigational New ...

FDA Lifts Clinical Hold on LogicBio Therapeutics' IND for LB-001 in pediatric patients with Methylmalonic Acidemia
09 May, 2022 FinancialContent

The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on LogicBioTherapeutics’ (NASDAQ: LOGC) ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
09 May, 2022 FinancialContent

Gainers TherapeuticsMD (NASDAQ:TXMD) shares rose 4466.2% to $7.0 during Monday's pre-market session. The ...

LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia
09 May, 2022 Yahoo! Finance

LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage company advancing a diversified pipeline of genetic medicines addressing rare disorders from infancy through adulthood, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the company's LB-001 Investigational New Drug Application (IND), allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial for pediatric patients with methylmalonic acidemia. In its letter, the FDA acknowledged

12 Health Care Stocks Moving In Friday's Pre-Market Session
06 May, 2022 FinancialContent

Gainers iRhythm Technologies (NASDAQ:IRTC) stock rose 21.6% to $143.58 during Friday's pre-market session. The ...

80 Biggest Movers From Yesterday
04 May, 2022 FinancialContent

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX ...

71 Biggest Movers From Yesterday
27 Apr, 2022 FinancialContent

Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product ...

Stocks That Hit 52-Week Lows On Wednesday
20 Apr, 2022 FinancialContent

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney ...

LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference
23 Mar, 2022 Yahoo! Finance

LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Gene Therapy and Gene Editing Conference. The presentation will be available on demand beginning at 7:00 a.m. ET on March 30, 2022.

LogicBio Therapeutics's Return On Capital Employed Insights
10 Mar, 2022 FinancialContent

According to Benzinga Pro data, during Q4, LogicBio Therapeutics (NASDAQ:LOGC) posted sales of $2.03 million. Earnings were up 11.02%, ...

LogicBio Therapeutics to Present at Barclays Global Healthcare Conference
08 Mar, 2022 Yahoo! Finance

LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will participate in a fireside chat during the Barclays Global Healthcare Conference on March 15, 2022, at 3:20 p.m. ET.

LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates
04 Mar, 2022 Yahoo! Finance

LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates.

Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
01 Mar, 2022 Yahoo! Finance

Agenus (AGEN) delivered earnings and revenue surprises of -62.50% and 46.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

UniQure (QURE) Tops Q4 Earnings and Revenue Estimates
25 Feb, 2022 Yahoo! Finance

uniQure (QURE) delivered earnings and revenue surprises of 123.61% and 129.68%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More
06 Feb, 2022 FinancialContent

Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came back up in the final session for a firm finish.

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
06 Feb, 2022 FinancialContent

Biotech stocks managed to close the week endingFeb. 4 with gains. Stocks recovered along with the broader markets early in the ...

LogicBio Therapeutics, Inc (LOGC) is a NASDAQ Common Stock listed in , ,

970x250